Use of pyrrobutamine in treatment of Rauwolfia-induced nasal congestion.
D018926:Anti-Allergic Agents; D004194:Disease; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D009296:Nasal Cavity; D009668:Nose Diseases; D010254:Paranasal Sinus Diseases; D011759:Pyrrolidines; D011926:Rauwolfia; D012110:Reserpine / Q000009:adverse effects*
D018926:Anti-Allergic Agents; D006634:Histamine H1 Antagonists; D011759:Pyrrolidines; D012110:Reserpine; C013665:pyrrobutamine
ANTIHISTAMINICS/therapeutic use; NASAL CAVITY/diseases; RESERPINE/injurious effects